

New Drugs in Hematology

Bologna, Royal Hotel Carlton
May 18-20, 2026

PROGRAM

Monday, May 18, 2026

09.00 am Welcome and introduction

SESSION I: A 5-Year Look at Three Amazing Therapeutic "SUDOKU Puzzle"

Chairman: P.L. Zinzani

09.15 am Diffuse large B-cell Lymphoma

G. Salles

09.40 am Multiple myeloma

M. Dimopoulos

10.05 am Chronic lymphocytic leukemia

S. Stilgenbauer

SESSION II: CAR-T

Chairman: S.J. Schuster

10.30 am Second generation auto-CAR-T

S.J. Schuster

10.50 am Allogeneic CAR-T: do they have a real future?

S.S. Neelapu

11.10 am In vivo CAR-T

T. Siddiqi

SESSION III: NEWS in Hodgkin's lymphoma

Chairman: A. Sureda

11.30 am Actual scenario in frontline advanced stage

P. Borchmann

11.45 am With the therapeutic revolution in 1L,
how will the second line be modified?

A. Sureda

12.00 pm New agents in R/R patients

R. Advani

12.15 pm The therapeutic algorithm for elderly and "Old old" patients

G. Collins

12.30 pm CAR-T: can we see the light at the end of the tunnel?

F. Locatelli

01.00 pm *Lunch*

LECTURES: update on BTK/BCL6 Degraders

Chairman: P.L. Zinzani

02.00 pm ZelebrudoMIDE (NX-2127) and BexobrutideG (NX-5948)

A.V. Danilov

02.15 pm BGB-16673

J. Seymour

02.30 pm Bifunctional cereblon-dependent ligand-directed
degrader of B cell Lymphoma 6

G. Salles

SESSION IV: Acute leukemias

Chairmen: A. Curti, A. Venditti

02.50 pm BCL-2 inhibitors in AML: beyond venetoclax

A. Wei

03.05 pm Antibody-Drug Conjugates in AML:
novel targets for novel drugs

A. Curti

03.20 pm Triplet therapy in AML: a myth or the next frontier

N.G. Daver

03.35 pm IDH inhibitors in AML

S. De Botton

04.00 pm *Coffee break*

04.30 pm Targeting FLT3: how to choose among inhibitors

A.E. Perl

04.45 pm Menin-inhibitors in AML and ALL

C. Papayannidis

05.00 pm Immunotherapies in AML and ALL

M. Subklewe

05.15 pm BCL-2 inhibition in ALL

E.J. Jabbour

Tuesday, May 19, 2026

SESSION V: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: F. Palandri, P. Guglielmelli

08.30 am Interferons and epigenetic modulators:

redefining the therapeutic Landscape in PV

J.J. Kiladjian

08.45 am Iron metabolism modifiers in PV

M. Kremyanskaya

09.00 am Evolving strategies for cytopenic myelofibrosis

P. Guglielmelli

09.15 am Epigenetic modifiers and
pro-apoptotic agents in myelofibrosis

P. Vachhani

09.30 am Monoclonal and bispecific antibodies
targeting mutant CALR

A. Rampotas

09.45 am Best timing and patient selection for
allogeneic transplantation in MF

N. Kroeger

10.10 pm *Coffee break*

SESSION VI: Non-Hodgkin's lymphoma (I)

Chairmen: C. Carlo-Stella, P. Corradini

Bispecific antibodies in combinations

10.30 am Epcoritamab

L. Falchi

10.45 am Glofitamab

M. Hutchings

11.00 am Mosunetuzumab

E. Budde

11.15 am Odronextamab

W.S. Kim

New bispecific and trispecific antibodies

11.30 am Surovatamig

S. Gaballa

11.45 am BAFFR bispecific

K. Patel

12.00 pm Trispecific antibodies

M. Subklewe

Monoclonal antibodies and ADC combinations

12.15 pm Tafasitamab combinations

J. Duell

12.30 pm Loncastuximab combinations

J.P. Alderuccio

12.45 pm Polatuzumab combinations

L. Sehn

01.15 pm Lunch

SESSION VII: Non-Hodgkin's lymphoma (II)

Chairmen: M. Ladetto, M. Martelli

BTK inhibitors combinations

02.15 pm Ibrutinib

K. Patel

02.30 pm Zanubrutinib

P.L. Zinzani

02.45 pm Acalabrutinib

P. Strati

03.00 pm Pirtobrutinib

M. Wang

BCL-2 inhibitors

03.15 pm Sonrotoclax

M. Wang

03.30 pm BGB-21447-101

F. Li

SESSION VIII: Non-Hodgkin's lymphoma (III)

Chairmen: A. Pinto, M. Spina

04.00 pm DZD8586, a non-covalent BBB penetrant LYN/BTK inhibitor

04.15 pm Golcadomide

04.30 pm Duvelisib

04.45 pm Mogamulizumab in combinations

05.00 pm Zeprumetostat (SHR2554)

05.15 pm DR-01

Y. Song

J.M. Michot

S.M. Horwitz

A. De Masson

Y. Song

S.P. Iyer

SESSION IX: Chronic myeloid leukemia

Chairmen: M. Breccia, F. Castagnetti

05.30 pm CML treatment recommendations

05.45 pm Asciminib

06.00 pm Ponatinib

06.15 pm Vodobatinib

06.30 pm Olverembatinib

06.45 pm TERN-701, ELVN-001 and other new agents

A. Hochhaus

M. Breccia

F. Castagnetti

F.E. Nicolini

D. Rea

M. Mauro

Wednesday, May 20, 2026**LECTURES**

Chairman: A. Tedeschi

08.30 am Novel therapies for Waldenström's macroglobulinemia

08.50 am News from Castleman disease

S. Treon

F. van Rhee

SESSION X: Chronic lymphocytic leukemia

Chairmen: P. Sportoletti A. Tedeschi

09.15 am First line:

- Until the progression
- Fixed duration

C. Tam

M.S. Davids

09.45 am Round table: analyzing the guide lines!

Chairman: P. Ghia

Discussants: C. Tam, M.S Davids, P.M. Barr, M. Shadman

10.30 am Pirtobrutinib

10.45 am Novel agents

P.M. Barr

M. Shadman

SESSION XI: Multiple myeloma

Chairmen: M. Dimopoulos, E. Zamagni

11.15 am New CARTs in relapsed/refractory patients

11.30 am Bispecifics against BCMA and GPRC5D

in relapsed/refractory patients

11.45 am Bispecifics in combination and trispecifics

in relapsed/refractory patients

12.00 pm Moving forward: immunotherapies in newly diagnosed

12.15 pm Celmods alone and in combination

in newly diagnosed and relapsed/refractory patients

12.30 pm ADC combinations in newly diagnosed

and relapsed/refractory patients

T. Martin

P. Rodriguez Otero

N. van de Donk

M. Raab

S. Lonial

E. Terpos

01.00 pm Arrivederci